All In Biotech

Drug Trial Radar · NCT00134264

A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease

Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents

Last checked: Nov 19, 2026Latest source record: Feb 3, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 15,067 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

15,067

Actual

Start

Jul 2004

Primary completion

Jun 2007

Study completion Jun 2007

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Aug 24, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 45 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To demonstrate if torcetrapib/atorvastatin can reduce the risk for major cardiovascular disease events, when compared to atorvastatin alone, in patients with coronary heart disease or risk equivalents

Conditions

  • Coronary Disease
  • Diabetes Mellitus

Interventions

  • torcetrapib/atorvastatinDrug

  • atorvastatinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The time to first occurrence of a major cardiovascular disease event

Locations

221 sites in 7 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Alabaster, Alabama

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    Gilbert, Arizona

  • Pfizer Investigational Site

    Phoenix, Arizona

  • Pfizer Investigational Site

    Tucson, Arizona

  • Pfizer Investigational Site

    Fresno, California

  • Pfizer Investigational Site

    Los Angeles, California

  • Pfizer Investigational Site

    Modesto, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    Santa Rosa, California

  • Pfizer Investigational Site

    Tustin, California

  • Pfizer Investigational Site

    Walnut Creek, California

  • Pfizer Investigational Site

    Denver, Colorado

  • Pfizer Investigational Site

    Longmont, Colorado

  • Pfizer Investigational Site

    Guilford, Connecticut

  • Pfizer Investigational Site

    Hartford, Connecticut

  • Pfizer Investigational Site

    Washington D.C., District of Columbia

  • Pfizer Investigational Site

    Clearwater, Florida

  • Pfizer Investigational Site

    Coral Gables, Florida

  • Pfizer Investigational Site

    Fort Meyers, Florida

  • Pfizer Investigational Site

    Jacksonville, Florida

  • Pfizer Investigational Site

    Jacksonville Beach, Florida

  • Pfizer Investigational Site

    Lakeland, Florida

  • Pfizer Investigational Site

    Orlando, Florida

  • Pfizer Investigational Site

    Pensacola, Florida

  • Pfizer Investigational Site

    Port Charlotte, Florida

  • Pfizer Investigational Site

    Sarasota, Florida

  • Pfizer Investigational Site

    West Palm Beach, Florida

  • Pfizer Investigational Site

    Atlanta, Georgia

  • Pfizer Investigational Site

    Aurora, Illinois

  • Pfizer Investigational Site

    Blue Island, Illinois

  • Pfizer Investigational Site

    Chicago, Illinois

  • Pfizer Investigational Site

    Evansville, Indiana

  • Pfizer Investigational Site

    Fort Wayne, Indiana

  • Pfizer Investigational Site

    Davenport, Iowa

  • Pfizer Investigational Site

    Des Moines, Iowa

  • Pfizer Investigational Site

    Iowa City, Iowa

  • Pfizer Investigational Site

    Wichita, Kansas

  • Pfizer Investigational Site

    Witchita, Kansas

  • Pfizer Investigational Site

    Louisville, Kentucky

Showing 40 of 221 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.